Drug R&D is the core competence for the sustainable development of Zelgen. We have established two R&D centers located in Kunshan, Jiangsu Province and Zhangjiang, Shanghai respectively. We have built a world-class R&D system centered on two proprietary technology platforms: a small-molecule drug R&D platform, and a bispecific/trispecific antibody and complex recombinant protein R&D platform. Through differentiated yet synergistic platform configurations, we have enhanced our R&D capabilities and industry position in the field of oncology, enabling efficient and continuous pipeline advancement.

Kunshan R&D Center.
Our R&D Center is located in the Kunshan High-tech Industrial Development Zone (昆山高新技術產業開發區), focuses on the research and development of recombinant protein drugs and antibody drugs. This center has capabilities that include molecular biology, cell biology, pilot-scale cell culture, protein purification, lyophilization, and quality control, and capacity to generate multiple IND filings. A kilo-lab for APIs, a pilot production laboratory for tablets/capsules and quality control laboratory have been also established in Kunshan. 

Shanghai R&D Center. 

Our R&D Center is located in Zhangjiang Science City (張江科學城) with small-molecule drug synthesis, formulation development and analysis laboratories, which can complete R&D work include new drug design, synthesis, screening, process development and process optimization, quality control et al. Our Preclinical Department, Clinical Operation Department, Medical Department, Statistics Department and Regulatory Department are located in Shanghai thus forming a complete R&D system for CMC research, preclinical and clinical research.